The Value of Negative-Pressure Wound Therapy and Flap Surgery in Hidradenitis Suppurativa - A Single Center Analysis of Different Treatment Options.
acne inversa
bacterial burden
flap surgery
hidradenitis suppurativa
negative-pressure wound therapy
Journal
Frontiers in surgery
ISSN: 2296-875X
Titre abrégé: Front Surg
Pays: Switzerland
ID NLM: 101645127
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
02
2022
accepted:
31
05
2022
entrez:
15
7
2022
pubmed:
16
7
2022
medline:
16
7
2022
Statut:
epublish
Résumé
Hidradenitis suppurativa is manifested by painful abscesses and scarring of sweat glands. Axillary, inguinal and genital regions are mostly affected. Multiple options exist in the treatment of hidradenitis suppurativa. The aim of this retrospective, mono-center cohort study was to analyze the outcome of different treatment methods after radical excision of hidradenitis suppurativa. We retrospectively evaluated the treatment strategy and recurrence rate of hidradenitis suppurativa. We included all eligible patients of legal age between February 2003 and October 2021, with the diagnosis of Hidradenitis suppurativa and the necessity for surgical treatment. All patients with surgical treatment and direct wound closure by suture were excluded. Bacterial load and flora were analyzed for primary and secondary reconstruction in combination with negative-pressure wound therapy. Patient data were analyzed for recurrence rate and remission time according to different reconstructive techniques. In 44 affected anatomical sites ( Radical excision of hidradenitis suppurativa as gold standard for surgical treatment combined with negative-pressure wound therapy as multi-stage procedures ultimately reduced bacterial load and flora in our study. The use of split
Sections du résumé
Background
UNASSIGNED
Hidradenitis suppurativa is manifested by painful abscesses and scarring of sweat glands. Axillary, inguinal and genital regions are mostly affected. Multiple options exist in the treatment of hidradenitis suppurativa. The aim of this retrospective, mono-center cohort study was to analyze the outcome of different treatment methods after radical excision of hidradenitis suppurativa.
Methods
UNASSIGNED
We retrospectively evaluated the treatment strategy and recurrence rate of hidradenitis suppurativa. We included all eligible patients of legal age between February 2003 and October 2021, with the diagnosis of Hidradenitis suppurativa and the necessity for surgical treatment. All patients with surgical treatment and direct wound closure by suture were excluded. Bacterial load and flora were analyzed for primary and secondary reconstruction in combination with negative-pressure wound therapy. Patient data were analyzed for recurrence rate and remission time according to different reconstructive techniques.
Results
UNASSIGNED
In 44 affected anatomical sites (
Conclusion
UNASSIGNED
Radical excision of hidradenitis suppurativa as gold standard for surgical treatment combined with negative-pressure wound therapy as multi-stage procedures ultimately reduced bacterial load and flora in our study. The use of split
Identifiants
pubmed: 35836613
doi: 10.3389/fsurg.2022.867487
pmc: PMC9273893
doi:
Types de publication
Journal Article
Langues
eng
Pagination
867487Informations de copyright
Copyright © 2022 Stumpfe, Horch, Arkudas, Cai, Mueller-Seubert, Hauck and Ludolph.
Déclaration de conflit d'intérêts
R. E. H. has received third party funding for scientific research on NPWT from KCI—an Acelity company in the past and has served as a member of a Scientific Advisory Board of KCI-Acelity in the past. R. E. H. and A. A. served as speakers on scientific symposia of KCI-Acelity in the past. The authors have no other relevant affiliations or financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Références
Handchir Mikrochir Plast Chir. 2021 Dec;53(6):519-525
pubmed: 33951736
Chirurg. 2021 Dec;92(12):1159-1170
pubmed: 33904942
Int Wound J. 2019 Apr;16(2):503-510
pubmed: 30604928
Dermatol Surg. 2020 Aug;46(8):e1-e7
pubmed: 32235148
J Am Acad Dermatol. 2015 Nov;73(5 Suppl 1):S70-7
pubmed: 26470621
Plast Reconstr Surg. 2014 Mar;133(3):370e-377e
pubmed: 24572882
Indian J Dermatol Venereol Leprol. 2019 May-Jun;85(3):248-257
pubmed: 30924446
South Med J. 1998 Dec;91(12):1107-14
pubmed: 9853721
BMC Dermatol. 2012 Jun 26;12:9
pubmed: 22734714
Br J Plast Surg. 2003 Jul;56(5):451-61
pubmed: 12890458
Cells. 2021 Aug 31;10(9):
pubmed: 34571907
Int Wound J. 2017 Feb;14(1):35-39
pubmed: 26663439
Int Wound J. 2020 Oct;17(5):1496-1507
pubmed: 32573103
Zentralbl Chir. 2006 Apr;131 Suppl 1:S170-3
pubmed: 16575674
Dermatology. 2020;236(5):393-412
pubmed: 32408306
Plast Reconstr Surg. 2021 Mar 1;147(3):479-491
pubmed: 33620946
Expert Rev Med Devices. 2020 Feb;17(2):139-148
pubmed: 31920139
Front Oncol. 2020 Mar 05;10:177
pubmed: 32195171
Scand J Plast Reconstr Surg Hand Surg. 2001 Sep;35(3):305-9
pubmed: 11680401
Int Wound J. 2015 Jun;12(3):334-7
pubmed: 23834292
Biofabrication. 2021 Jul 13;13(4):
pubmed: 34157687
Microsurgery. 2022 May;42(4):372-375
pubmed: 34783366
Int Wound J. 2021 Dec;18(6):942-943
pubmed: 34498375
J Pers Med. 2021 Oct 24;11(11):
pubmed: 34834428
Ann Plast Surg. 1987 Mar;18(3):230-7
pubmed: 2954503
Int Wound J. 2018 Dec;15(6):978-984
pubmed: 29974664
Int Wound J. 2021 Dec;18(6):932-939
pubmed: 34128314
Ann Plast Surg. 2011 Oct;67(4):397-401
pubmed: 21587057
Clin Hemorheol Microcirc. 2019;72(4):365-374
pubmed: 30909192
J Cell Mol Med. 2006 Jan-Mar;10(1):4-6
pubmed: 16563217
Microcirculation. 2022 Feb;29(2):e12742
pubmed: 34863000
Wounds. 2020 Dec;32(12):E101-E105
pubmed: 33476290
Dermatol Surg. 2021 Apr 1;47(4):e106-e110
pubmed: 33795566
Zentralbl Chir. 2018 Dec;143(6):609-616
pubmed: 30537781
Dermatol Surg. 2018 Oct;44(10):1323-1331
pubmed: 30204742
Int Wound J. 2020 Feb;17(1):117-123
pubmed: 31680472
Tissue Eng Part A. 2021 Jan;27(1-2):129-141
pubmed: 32524901
Zentralbl Chir. 2004 May;129 Suppl 1:S129-32
pubmed: 15168310
Cells. 2021 Aug 13;10(8):
pubmed: 34440843
Int J Low Extrem Wounds. 2004 Sep;3(3):168-71
pubmed: 15866810
Cureus. 2018 Sep 17;10(9):e3319
pubmed: 30473952
Int Wound J. 2016 Feb;13(1):77-81
pubmed: 24618357
Biomed Mater. 2021 Sep 06;16(6):
pubmed: 34406979